Background Bamlanivimab is routinely used in the treatment of coronavirus disease 2019
(COVID-19) in worldwide. We performed a meta-analysis to investigate the efficacy and …

Regdanvimab has decreased the time to clinical recovery from coronavirus disease 2019
(COVID-19) and lowered the rate of oxygen therapy according to the results from Phase 2 …

Monoclonal antibody (mAb) therapy has emerged as one of the mainstay treatment options
for SARS-CoV-2. To improve speed of delivery and decrease bedside nursing needs …

Aim. To evaluate the efficacy and safety of a combination of virus-neutralizing monoclonal
antibodies–MAB (casirivimab and imdevimab) in patients with mild to moderate COVID-19 …

Objectives: We aimed to examine the effectiveness of tixagevimab–cilgavimab (Evusheld)
during the coronavirus disease 2019 (COVID-19) B. 1.1. 529, BA. 4, and BA. 5 surges …

Introduction: The casirivimab and imdevimab antibody cocktail has proven to be extremely
effective against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta …

Background: This study aims to evaluate the real-world effectiveness of regdanvimab on
clinical outcomes in patients with mild to moderate coronavirus disease 2019 (COVID-19) …

Aims This study aimed to evaluate the efficacy and safety of regdanvimab, an anti‐SARS‐
COV‐2 monoclonal antibody approved by the European Medicines Agency in November …

BACKGROUND: Most patients infected with SARS-CoV-2, resulting in COVID-19, have only
mild symptoms that can be managed in an ambulatory setting. However, a significant …

Background and objectives In 2020, the world was profoundly affected by the spread of
SARS-CoV-2, a novel coronavirus first identified in December 2019, that was the causative …